Literature DB >> 8022042

Hemochromatosis, multiorgan hemosiderosis, and coronary artery disease.

M Miller1, G M Hutchins.   

Abstract

OBJECTIVE: To examine the prevalence of coronary artery disease (CAD) in autopsies of patients with iron-overload syndromes.
DESIGN: Retrospective autopsy study of CAD in cases of hemochromatosis and multiorgan hemosiderosis.
SETTING: Registry of nearly 48,000 autopsies performed at The Johns Hopkins Hospital between 1889 and 1992.
SUBJECTS: One hundred twenty-three subjects were studied. In a 2:1 control-case ratio, 82 controls matched by age, race, and sex were compared with 41 cases with iron overload. MAIN OUTCOME MEASURE: Severity of CAD.
RESULTS: Pathological description of the coronary arteries were recorded as advanced or severe in 12% of iron-overload cases (n = 41) (mean age, 57.6 +/- 13.2 years) compared with 38% of controls (n = 82) (mean age, 57.0 +/- 13.8 years) (P = .01). The prevalence of three-vessel disease assessed by postmortem coronary arteriography was 11.1% in iron-overload cases (n = 18) (mean age, 61.7 +/- 12.2 years) compared with 33.3% in controls (n = 36) (mean age, 61.1 +/- 12.5 years) (P = .04). The odds ratio of CAD with iron overload was 0.18 (95% confidence interval, 0.04 to 0.73).
CONCLUSIONS: Iron overload resulting from hemochromatosis or multiorgan hemosiderosis is not associated with an increased prevalence of CAD.

Entities:  

Mesh:

Year:  1994        PMID: 8022042

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  15 in total

1.  Possible association of a reduction in cardiovascular events with blood donation.

Authors:  D G Meyers; D Strickland; P A Maloley; J K Seburg; J E Wilson; B F McManus
Journal:  Heart       Date:  1997-08       Impact factor: 5.994

2.  Iron overload diminishes atherosclerosis in apoE-deficient mice.

Authors:  E A Kirk; J W Heinecke; R C LeBoeuf
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

3.  Design and Rationale for the Study of Changes in Iron and Atherosclerosis Risk in Perimenopause.

Authors:  Georgeta Mihai; Xin He; Xiaolan Zhang; Beth McCarthy; Tam Tran; Michael Pennell; Jessica Blank; Orlando P Simonetti; Rebecca D Jackson; Subha V Raman
Journal:  J Clin Exp Cardiolog       Date:  2011

4.  Ironing-Out the Role of Hepcidin in Atherosclerosis.

Authors:  Liang Guo; Atsushi Sakamoto; Anne Cornelissen; Charles C Hong; Aloke V Finn
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

5.  Disordered vascular compliance in haemochromatosis.

Authors:  W J Cash; S O'Neill; M E O'Donnell; D R McCance; I S Young; J McEneny; I S Cadden; Neil I McDougall; M E Callender
Journal:  Ir J Med Sci       Date:  2013-09-03       Impact factor: 1.568

Review 6.  The role of hepcidin and iron homeostasis in atherosclerosis.

Authors:  Florian Wunderer; Lisa Traeger; Haakon H Sigurslid; Patrick Meybohm; Donald B Bloch; Rajeev Malhotra
Journal:  Pharmacol Res       Date:  2020-01-25       Impact factor: 7.658

7.  HFE mutations in heart disease.

Authors:  Terence Dunn; Derek Blankenship; Nicole Beal; Richard Allen; Eliot Schechter; William Moore; Ghazala Perveen; June Eichner
Journal:  Heart Vessels       Date:  2008-09-20       Impact factor: 2.037

Review 8.  Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?

Authors:  Harsh Goel; Joshua R Hirsch; Anita Deswal; Saamir A Hassan
Journal:  Curr Atheroscler Rep       Date:  2021-08-10       Impact factor: 5.113

9.  A comparison between whites and blacks with severe multi-organ iron overload identified in 16,152 autopsies.

Authors:  James C Barton; Ronald T Acton; Laura E Anderson; C Bruce Alexander
Journal:  Clin Gastroenterol Hepatol       Date:  2009-03-21       Impact factor: 11.382

Review 10.  The role of iron metabolism as a mediator of macrophage inflammation and lipid handling in atherosclerosis.

Authors:  Anwer Habib; Aloke V Finn
Journal:  Front Pharmacol       Date:  2014-08-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.